medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2023, Number 3

<< Back Next >>

Sal Jal 2023; 10 (3)

Serologic biomarkers of risk in non-Hodgkin's lymphoma

Sosa-Quintero LS, Barreno-Rocha SG, Guzmán-Silahua S, Ornelas-Ibarra GG, Demis-Eliseo LG, Rubio-Jurado B, Nava-Zavala AH

Language: Spanish
References: 56
Page: 164-172
PDF size: 242.26 Kb.


ABSTRACT

Lymphomas belong to a group of neoplasms that originate from the malignant proliferation of lymphocytes. Globocan reports that in Mexico, Non-Hodgkin's lymphoma (NHL) occupies the 11th place in new cases with 5,174 annually, as well as the 11th place in deaths with 2,741 per year, with a 5-year prevalence of 14,189 cases. Over the years, several prognostic indices based on the clinical characteristics of the patient have allowed the establishment of a prognostic profile based on identified factors, which allows the implementation of treatment strategies. Molecular studies allow the identification of new biomarkers related to lymphomas at the genetic, epigenetic and proteomic levels, as well as in the tumor microenvironment. The application of next-generation sequencing technologies offers the opportunity for the detection of new molecular biomarkers involved in the pathophysiological mechanisms of lymphomagenesis, allowing for improved classification, diagnosis and prognosis. Given the emergence of numerous biomarkers, there is an urgent challenge to select those that can be applicable in clinical practice, reproducible, validate them and identify their cost-effectiveness. The dynamic interaction of the different factors involved in the development, evolution and prognosis of lymphomas, in addition to the appropriate application of biomarkers, will facilitate the transition to personalized medicine in patients with lymphoma.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

  2. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021.

  3. Luo J, Craver A, Bahl K, Stepniak L, Moore K, King J, et al. Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies. J Natl Cancer Cent. 2022;2(4):226-234.

  4. American Cancer Society. Cancer Facts and Figures 2023. Atlanta, GA: American Cancer Society; 2023.

  5. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015;15(5):531-544.

  6. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel). 2021;9(1):5.

  7. Mafra A, Laversanne M, Gospodarowicz M, Klinger P, De Paula Silva N, Piñeros M, et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 2022;151(9):1474-1481.

  8. GLOBOCAN. Non-Hodgkin lymphoma. United States of America Statistics: World Health Organization; 2020.

  9. Cancer Today. Data visualization tools for exploring the global cancer burden in 2020. OMS; 2020 [updated 2020; cited 2021 12 December]. Available in: http://gco.iarc.fr/today

  10. GLOBOCAN. Estimated number of prevalent cases in 2020, Mexico, both sexes, all ages. OMS; 2020.

  11. Guía de Práctica Clínica. Linfomas no Hodgkin en el adulto. México: Secretaría de Salud; 2009. Disponible en: http://www.facmed.unam.mx/sg/css/GPC/SIDSS-GPC/gpc/docs/IMSS-174-09-ER.pdf

  12. Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145-186.

  13. Okuyama A, Shibata A, Nishimoto H. Critical points for interpreting patients' survival rate using cancer registries: a literature review. J Epidemiol. 2018;28(2):61-66.

  14. Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. SEER Cancer statistics review. Bethesda, MD: National Cancer Institute; 2015. Available in: https://seer.cancer.gov/csr/1975_2016

  15. Sapkota S, Shaikh H. Non-Hodgkin lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.

  16. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.

  17. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.

  18. Munakata W, Terauchi T, Maruyama D, Nagai H. Revised staging system for malignant lymphoma based on the Lugano classification. Jpn J Clin Oncol. 2019;49(10):895-900.

  19. Hoppe R DV, Mauch P, Armitage J. Clinical evaluation and staging of Hodgkin lymphoma. In: Armitage J, Diehl V, Hoppe R, editor. Hodgkin lymphoma. 2nd ed. United States of America: Lippincott Williams & Wilkins; 2007. p. 466.

  20. Kaplan HS, Rosenberg SA. The treatment of Hodgkin's disease. Med Clin North Am. 1966;50(6):1591-1610.

  21. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26(6):1063-1083.

  22. Lukes RJ, Craver LF, Hall TC, Rappaport H, Ruben P. Report of the nomenclature committee. Cancer Res. 1966;26:1311.

  23. Peters MV. The need for a new clinical classification in Hodgkin's disease: keynote address. Cancer Res. 1971;31(11):1713-1722.

  24. Musshoff K, Renemann H, Boutis L, Afkham J. Extranodular lymphogranulomatosis--diagnosis, therapy and prognosis in two different types of organ involvement. Contribution to the phase classification of Hodgkin's disease. Fortschr Geb Rontgenstr Nuklearmed. 1968;109(6):776-786.

  25. Rosenberg SA, Kaplan HS. Hodgkin's disease and other malignant lymphomas. Calif Med. 1970;113(4):23-38.

  26. Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, et al. Report of the Committee on Hodgkin's disease staging procedures. Cancer Res. 1971;31(11):1862-1863.

  27. Tubiana M, Attié E, Flamant R, Gérard-Marchant R, Hayat M. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res. 1971;31(11):1801-1810.

  28. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31(11):1860-1861.

  29. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-1636.

  30. Hoppe R, Mauch P, Armitage J. Prognostic factors in Hodgkin lymphoma. In: Armitage J, Diehl V, Hoppe R, editor. Hodgkin lymphoma. 2nd ed. United States of America: Lippincott Williams & Wilkins; 2007. p. 466.

  31. Yildiz Celtek N, Suren M, Demir O, Okan I. Karnofsky performance scale validity and reliability of Turkish palliative cancer patients. Turk J Med Sci. 2019;49(3):894-898.

  32. Ciampi A, Bush RS, Gospodarowicz M, Till JE. An approach to classifying prognostic factors related to survival experience for non-Hodgkin's lymphoma patients: based on a series of 982 patients: 1967-1975. Cancer. 1981;47(3):621-627.

  33. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2003;362(9378):139-146.

  34. Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989;59(2):276-282.

  35. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982;50(12):2699-2707.

  36. Sapkota S, Shaikh H. Non-Hodgkin lymphoma. StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2022.

  37. Velasquez WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR, et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood. 1989;74(2):551-557.

  38. Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7(10):1518-1527.

  39. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7(8):1018-1026.

  40. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.

  41. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562.

  42. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.

  43. Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, et al. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma. 2014;55(4):802-810.

  44. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.

  45. Rubio-Jurado B, Sosa-Quintero LS, Carrasco-Martinez IL, Norato-Delgado A, Garcia-Luna E, Guzman-Silahua S, et al. New biomarkers in non-Hodgkin lymphoma and acute leukemias. Adv Clin Chem. 2020;96:19-53.

  46. Purnamasidhi CAW, Suega K, Bakta IM. Association between lactate dehydrogenase levels to the response of non-Hodgkin lymphoma in elderly patients who treated with first-line chemotherapy in sanglah general hospital. Open Access Maced J Med Sci. 2019;7(12):1984-1986.

  47. Üsküdar Teke H, Gündüz E, Akay OM, Bal C, Gülbas Z. Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-Hodgkin lymphoma patients? Turk J Haematol. 2015;32(1):21-28.

  48. Jiang L, Li N. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis. 2020;23(4):515-529.

  49. Duletic-Nacinovic A, Gacic V, Valkovic T, Lucin K, Fisic E, Zuvic-Butorac M, et al. Concurrent elevations of VEGF, osteopontin and MCP-1 serum levels are independent predictors of survival in patients with diffuse large B-cell lymphoma. Acta Haematol. 2016;136(1):52-61.

  50. Li YL, Shi ZH, Wang X, Gu KS, Zhai ZM. Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma. Ann Hematol. 2019;98(2):413-422.

  51. Pamuk GE, Tozkir H, Uyanik MS, Gurkan H, Duymaz J, Pamuk ON. CXCL12 rs18011157 polymorph?sm in patients w?th non-Hodgkin's lymphoma: Is it associated with poor outcome? J Cancer Res Ther. 2018;14(5):1075-1078.

  52. Ghedini GC, Ronca R, Presta M, Giacomini A. Future applications of FGF/FGFR inhibitors in cancer. Expert Rev Anticancer Ther. 2018;18(9):861-872.

  53. Gao L, Feng Z, Li Q, Li L, Chen L, Xiao T. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma. Tumour Biol. 2014;35(4):2997-3002.

  54. Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol. 2019;10(3):136-148.

  55. Yu DD, Liu HL, Bai YL, Wu B, Chen WH, Ren JH, et al. Correlation between increased circulating endothelial progenitor cells and stage of non-Hodgkin lymphoma. J Huazhong Univ Sci Technolog Med Sci. 2013;33(2):284-287.

  56. Annese T, Tamma R, Ribatti D. Endothelial progenitor cells from bench to antitumor therapy and diagnostic imaging. In: Haider KH, editor. Handbook of stem cell therapy. Singapore: Springer Singapore; 2022. pp. 1-31.




2020     |     www.medigraphic.com